Overview
Zanubrutinib is a highly selective Bruton tyrosine kinase (BTK) inhibitor. Zanubrutinib forms a covalent bond with a cysteine residue in the BTK active site to inhibit BTK activity. BTK is a signaling molecule of the B-cell antigen receptor and cytokine receptor pathways. BTK signals activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Zanubrutinib inhibits malignant B-cell proliferation and reduces tumor growth.

Coverage Guidelines
Authorization may be granted for members who are currently receiving treatment with Brukinsa excluding when the product is obtained as samples or via manufacturer’s patient assistance programs. OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:
1. The member is ≥ 18 years of age
2. The member is using Brukinsa for the treatment of mantle cell lymphoma
3. The member has had 1 prior therapy for mantle cell lymphoma
4. Provider specialty is oncology/hematology, or the medication is being prescribed in consultation with oncologist or hematologist

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s condition.

Limitations
1. Initial approvals and reauthorizations will be for 12 months.
2. The following quantity limits apply:

| Brukinsa 80mg | 120 capsules per 30 days |

References

Review History
07/22/2020 – Reviewed at P&T. Effective 9/1/2020

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.